参考文献/References:
[1] Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas[J]. Acta Neuropathol, 2005, 109(1): 93-108.
[2] Kilday JP, Bartels UK, Bouffet E. Targeted therapy inpediatric low-grade glioma [J]. Curr Neurol Neurosci Rep, 2014, 14(4): 441.
[3] Berger MS, Carter BS. Low grade gliomas [J]. NeurosurgFocus, 2013, 34(2): 1.
[4] Carabenciov ID, Buckner JC. Controversies in the therapy of low-grade gliomas [J]. Curr Treat Options Oncol, 2019, 20(4): 25.
[5] Wang L, Zhang Q, Wu P, et al. SLC12A5 interacts andenhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7 [J]. Cancer Sci, 2020, 111(7): 2349-2360.
[6] Liu JY, Dai YB, Li X, et al. Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway[J]. Cell Death Dis, 2017, 8(3): e2691.
[7] Yang GP, He WP, Tan JF, et al. Overexpression of SLC12A5is associated with tumor progression and poor survival in ovarian carcinoma [J]. Int J Gynecol Cancer, 2019, 29(8): 1280-1284.
[8] Yu C, Yu J, Yao X, et al. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing [J]. Cell Res, 2014, 24(6): 701-712.
[9] Xu L, Li X, Cai M, et al. Increased expression of solutecarrier family 12 member 5 via gene amplification contri-butes to tumour progression and metastasis and associates with poor survival in colorectal cancer [J]. Gut, 2016, 65(4): 635-646.
[10] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analy-ses [J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[11] Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018 [J]. Nucl Acids Res, 2018, 46(W1): W60-W64.
[12] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11:protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucl Acids Res, 2019, 47(D1): D607-D613.
[13] Zhou Y, Zhou B, Pache L, et al. Metascape provides a biolo-gist-oriented resource for the analysis of systems-level datasets [J]. Nat Commun, 2019, 10(1): 1523.
[14] Zhao Q, Zhu Y, Liu L, et al. STK39 blockage by RNAinterference inhibits the proliferation and induces the apoptosis of renal cell carcinoma [J]. Onco Targets Ther,2018, 11: 1511-1519.
[15] Huang T, Zhou Y, Cao Y, et al. STK39, overexpressed inosteosarcoma, regulates osteosarcoma cell invasion and proliferation [J]. Oncol Lett, 2017, 14(4): 4599-4604.
[16] Li C, Wang A, Chen Y, et al. MicroRNA-299-5p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39 [J]. Oncol Rep, 2020, 43(4): 1221-133.
[17] Zhang C, Wang X, Fang D, et al. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway [J]. Theranostics, 2021, 11(5): 2108-2122.
[18] Yucebas M, Yilmaz Susluer S, Onur Caglar H, et al. Expres-sion profiling of RE1-silencing transcription factor (REST), REST corepressor 1 (RCOR1), and Synapsin 1 (SYN1) genes in human gliomas [J]. J BUON, 2016, 21(4): 964-972.
[19] Bomben VC, Turner KL, Barclay TT, et al. Transientreceptor potential canonical channels are essential for chemotactic migration of human malignant gliomas [J]. J Cell Physiol, 2011, 226(7): 1879-1888.
[20] Fung KM, Rorke LB, Giasson B, et al. Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medullo-blastomas [J]. Acta Neuropathol, 2003, 106(2): 167-175.